Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies

    Summary
    EudraCT number
    2013-004435-72
    Trial protocol
    GB   SE   DE   CZ   DK   LV   LT   AT   PT   EE   NL   NO   ES   GR   BE   HR   IT   SK   HU   BG   FR  
    Global end of trial date
    05 Oct 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Oct 2024
    First version publication date
    16 Oct 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GA28951
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02118584
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    F. Hoffmann-La Roche AG
    Sponsor organisation address
    Grenzacherstrasse 124, Basel, Switzerland, CH-4058
    Public contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Scientific contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 Oct 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    05 Oct 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The aim of the study is to evaluate the efficacy and safety of etrolizumab in participants with ulcerative colities (UC).
    Protection of trial subjects
    All study subjects were required to read and sign an Informed Consent Form.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    12 Sep 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 204
    Country: Number of subjects enrolled
    Poland: 163
    Country: Number of subjects enrolled
    Russian Federation: 119
    Country: Number of subjects enrolled
    Ukraine: 157
    Country: Number of subjects enrolled
    Brazil: 118
    Country: Number of subjects enrolled
    Czechia: 125
    Country: Number of subjects enrolled
    Hungary: 86
    Country: Number of subjects enrolled
    France: 79
    Country: Number of subjects enrolled
    Canada: 74
    Country: Number of subjects enrolled
    Korea, Republic of: 67
    Country: Number of subjects enrolled
    Germany: 60
    Country: Number of subjects enrolled
    United Kingdom: 59
    Country: Number of subjects enrolled
    Italy: 50
    Country: Number of subjects enrolled
    Belgium: 49
    Country: Number of subjects enrolled
    Australia: 43
    Country: Number of subjects enrolled
    India: 39
    Country: Number of subjects enrolled
    Serbia: 33
    Country: Number of subjects enrolled
    Slovakia: 31
    Country: Number of subjects enrolled
    Bulgaria: 29
    Country: Number of subjects enrolled
    Israel: 25
    Country: Number of subjects enrolled
    Spain: 23
    Country: Number of subjects enrolled
    New Zealand: 22
    Country: Number of subjects enrolled
    Lithuania: 21
    Country: Number of subjects enrolled
    South Africa: 17
    Country: Number of subjects enrolled
    Netherlands: 18
    Country: Number of subjects enrolled
    Estonia: 15
    Country: Number of subjects enrolled
    Austria: 15
    Country: Number of subjects enrolled
    Switzerland: 15
    Country: Number of subjects enrolled
    Mexico: 9
    Country: Number of subjects enrolled
    Romania: 8
    Country: Number of subjects enrolled
    Türkiye: 8
    Country: Number of subjects enrolled
    Latvia: 8
    Country: Number of subjects enrolled
    Malaysia: 7
    Country: Number of subjects enrolled
    Denmark: 6
    Country: Number of subjects enrolled
    Portugal: 4
    Country: Number of subjects enrolled
    Colombia: 4
    Country: Number of subjects enrolled
    Croatia: 4
    Country: Number of subjects enrolled
    Argentina: 3
    Country: Number of subjects enrolled
    Singapore: 2
    Country: Number of subjects enrolled
    Norway: 1
    Country: Number of subjects enrolled
    Greece: 1
    Country: Number of subjects enrolled
    Hong Kong: 1
    Worldwide total number of subjects
    1822
    EEA total number of subjects
    796
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    1724
    From 65 to 84 years
    98
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants took part in this study in 42 countries. All participants who were enrolled in this study previously took part in one of the following parent studies - Phase II: GA27927; Phase III: GA28948, GA28949, GA28950, GA29102, GA29103.

    Pre-assignment
    Screening details
    Study consists of 2 parts, Part 1: Open-label extension (OLE) period & Part 2: Progressive multifocal leukoencephalopathy (PML) safety monitoring (SM) period. A total of 1822 participants were enrolled in study, 1773 participants in Part 1 & 796 participants in Part 2. Of the 796, 49 participants were directly enrolled into Part 2: PML SM period.

    Period 1
    Period 1 title
    Part 1: Open Label Extension Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part 1 (OLE): Etrolizumab Only
    Arm description
    Participants received etrolizumab 105 milligrams (mg), subcutaneously (SC) every 4 weeks (Q4W) for maximum of 369.9 weeks, followed by a 12-week safety follow-up.
    Arm type
    Experimental

    Investigational medicinal product name
    Etrolizumab
    Investigational medicinal product code
    RO5490261
    Other name
    RG7413, PRO145223, rhuMAb Beta7
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etrolizumab, 105 mg, administered SC, Q4W for maximum of 369.9 weeks.

    Arm title
    Part 1 (OLE) to Part 2 (PML SM)
    Arm description
    Participants received etrolizumab 105 mg, SC, Q4W for maximum of 369.9 weeks, followed by a 12-week safety follow-up in the OLE period. After the OLE period, participants were given the option to enter Part 2 (PML SM). Participants who chose to enter the PML SM period were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.
    Arm type
    Experimental

    Investigational medicinal product name
    Etrolizumab
    Investigational medicinal product code
    RO5490261
    Other name
    RG7413, PRO145223, rhuMAb Beta7
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etrolizumab, 105 mg, administered SC, Q4W for maximum of 369.9 weeks in Part 1 (OLE) only. No treatment was administered in Part 2 (PML SM).

    Arm title
    Part 2 (PML SM) Only
    Arm description
    Participants from the Phase II or Phase III studies who were not eligible/did not wish to enroll in Part 1 (OLE), and had completed the 12-week safety follow-up period in their parent study were enrolled directly in Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    Part 1 (OLE): Etrolizumab Only Part 1 (OLE) to Part 2 (PML SM) Part 2 (PML SM) Only
    Started
    1026
    747
    49
    Completed
    9
    747
    49
    Not completed
    1017
    0
    0
         Physician decision
    128
    -
    -
         Reason Not specified
    135
    -
    -
         Adverse Event
    79
    -
    -
         Death
    9
    -
    -
         Unknown
    3
    -
    -
         Non-compliance
    12
    -
    -
         Withdrawal by Subject
    568
    -
    -
         Study Terminated by Sponsor
    29
    -
    -
         Lost to follow-up
    53
    -
    -
         Protocol deviation
    1
    -
    -
    Period 2
    Period 2 title
    Part 2: PML Safety Monitoring Period
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part 1 (OLE) to Part 2 (PML-SM)
    Arm description
    After the OLE period, participants were given the option to enter the Part 2 (PML SM). Participants who chose to enter the PML SM period were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Part 2: PML-SM Only
    Arm description
    Participants from the Phase II or Phase III studies who were not eligible/did not wish to enroll in Part 1 (OLE), and had completed the 12-week safety follow-up period in their parent study were enrolled directly in Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 2 [1]
    Part 1 (OLE) to Part 2 (PML-SM) Part 2: PML-SM Only
    Started
    747
    49
    Completed
    317
    43
    Not completed
    430
    6
         Physician decision
    10
    1
         Reason Not specified
    6
    -
         Adverse Event
    5
    -
         Death
    1
    -
         Non-compliance
    -
    1
         Withdrawal by Subject
    32
    1
         Study Terminated by Sponsor
    354
    -
         Lost to follow-up
    22
    3
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Participants were given the option to enter the PML SM period. Only 747 participants chose to join this period.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Part 1 (OLE): Etrolizumab Only
    Reporting group description
    Participants received etrolizumab 105 milligrams (mg), subcutaneously (SC) every 4 weeks (Q4W) for maximum of 369.9 weeks, followed by a 12-week safety follow-up.

    Reporting group title
    Part 1 (OLE) to Part 2 (PML SM)
    Reporting group description
    Participants received etrolizumab 105 mg, SC, Q4W for maximum of 369.9 weeks, followed by a 12-week safety follow-up in the OLE period. After the OLE period, participants were given the option to enter Part 2 (PML SM). Participants who chose to enter the PML SM period were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Reporting group title
    Part 2 (PML SM) Only
    Reporting group description
    Participants from the Phase II or Phase III studies who were not eligible/did not wish to enroll in Part 1 (OLE), and had completed the 12-week safety follow-up period in their parent study were enrolled directly in Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Reporting group values
    Part 1 (OLE): Etrolizumab Only Part 1 (OLE) to Part 2 (PML SM) Part 2 (PML SM) Only Total
    Number of subjects
    1026 747 49 1026
    Age categorical
    Units: Subjects
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    39.7 ( 13.3 ) 40.7 ( 14.1 ) 42.7 ( 15.2 ) -
    Sex: Female, Male
    Units: participants
        Female
    417 333 23 773
        Male
    609 414 26 1049
    Race/Ethnicity, Customized
    Units: Subjects
        American Indian or Alaska Native
    1 1 1 3
        Asian
    101 40 4 145
        Black or African American
    11 18 0 29
        White
    843 635 40 1518
        Other
    36 32 2 70
        Unknown
    33 20 2 55
        Multiple
    1 1 0 2
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    59 93 0 152
        Not Hispanic or Latino
    915 632 47 1594
        Unknown or Not Reported
    52 22 2 76

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Part 1 (OLE): Etrolizumab Only
    Reporting group description
    Participants received etrolizumab 105 milligrams (mg), subcutaneously (SC) every 4 weeks (Q4W) for maximum of 369.9 weeks, followed by a 12-week safety follow-up.

    Reporting group title
    Part 1 (OLE) to Part 2 (PML SM)
    Reporting group description
    Participants received etrolizumab 105 mg, SC, Q4W for maximum of 369.9 weeks, followed by a 12-week safety follow-up in the OLE period. After the OLE period, participants were given the option to enter Part 2 (PML SM). Participants who chose to enter the PML SM period were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Reporting group title
    Part 2 (PML SM) Only
    Reporting group description
    Participants from the Phase II or Phase III studies who were not eligible/did not wish to enroll in Part 1 (OLE), and had completed the 12-week safety follow-up period in their parent study were enrolled directly in Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.
    Reporting group title
    Part 1 (OLE) to Part 2 (PML-SM)
    Reporting group description
    After the OLE period, participants were given the option to enter the Part 2 (PML SM). Participants who chose to enter the PML SM period were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Reporting group title
    Part 2: PML-SM Only
    Reporting group description
    Participants from the Phase II or Phase III studies who were not eligible/did not wish to enroll in Part 1 (OLE), and had completed the 12-week safety follow-up period in their parent study were enrolled directly in Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Subject analysis set title
    Part 1 (OLE): Etrolizumab
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants received etrolizumab 105 mg, SC, Q4W for maximum of 369.9 weeks, followed by a 12-week safety follow-up.

    Subject analysis set title
    Part 2: PML-SM
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants from Part 1 (OLE) and from Phase II/III studies who were not eligible/did not wish to enroll in Part 1 (OLE) and had completed the 12-week safety follow-up period were enrolled in the Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Primary: Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS)

    Close Top of page
    End point title
    Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) [1]
    End point description
    The pMCS is a composite of 3 assessments, each rated from 0 (none) to 3 (severe disease): stool frequency, rectal bleeding, and physician’s global assessment. The total score for pMCS ranges from 0 (none) to 9 (severe disease). pMCS clinical remission was defined as pMCS ≤ 2, a rectal bleeding score of 0-1, physician’s global assessment of 0-1, stool frequency subscore of 0-1. Percentages have been rounded off. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study. Number analyzed is the number of participants with data available for analysis. "n"= number of participants with data available for analysis at the specified timepoint.
    End point type
    Primary
    End point timeframe
    Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312 and 324 weeks
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1772
    Units: percentage of participants
    number (not applicable)
        Baseline (n=1772)
    32.0
        Week 4 (n=1365)
    47.2
        Week 8 (n=1302)
    52.2
        Week 12 (n=1292)
    55.9
        Week 24 (n=935)
    63.7
        Week 36 (n=879)
    68.3
        Week 48 (n=856)
    73.4
        Week 60 (n=810)
    72.2
        Week 72 (n=768)
    75.4
        Week 84 (n=733)
    76.5
        Week 96 (n=718)
    72.2
        Week 108 (n=665)
    72.0
        Week 120 (n=593)
    77.4
        Week 132 (n=535)
    82.2
        Week 144 (n=501)
    80.0
        Week 156 (n=461)
    78.5
        Week 168 (n=410)
    81.0
        Week 180 (n=378)
    78.8
        Week 192 (n=355)
    80.8
        Week 204 (n=318)
    83.6
        Week 216 (n=289)
    84.8
        Week 228 (n=262)
    85.1
        Week 240 (n=230)
    82.6
        Week 252 (n=207)
    86.0
        Week 264 (n=164)
    84.8
        Week 276 (n=150)
    86.0
        Week 288 (n=136)
    82.4
        Week 300 (n=90)
    86.7
        Week 312 (n=62)
    87.1
        Week 324 (n=30)
    80.0
    No statistical analyses for this end point

    Primary: Part 1: Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS)

    Close Top of page
    End point title
    Part 1: Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS) [2]
    End point description
    The Mayo Clinic scoring system is a composite of 4 assessments for UC disease activity. The 4 component sub-scores are: 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment, each rated from 0‑3, 0 representing no pathology to 3 for severe disease. The minimum Mayo Score is 0 (no pathology) and the maximum is 12 (severe disease). MCS remission was defined as MCS ≤ 2, a rectal bleeding score of 0, physician’s global assessment of 0-1, stool frequency subscore of 0-1 and endoscopy score of 0-1. Percentage has been rounded off. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study. Number analyzed is the number of participants with data available for analysis.
    End point type
    Primary
    End point timeframe
    At OLE Week 108
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    623
    Units: percentage of participants
        number (not applicable)
    58.1
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Part 1: Number of Participants With Serious Adverse Events (SAEs) [3]
    End point description
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigation, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
    373
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With Adverse Events (AEs) and Severity of AEs Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 [NCI CTCAE v4.0]

    Close Top of page
    End point title
    Part 1: Number of Participants With Adverse Events (AEs) and Severity of AEs Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 [NCI CTCAE v4.0] [4]
    End point description
    AE is any untoward medical occurrence in participant administered a pharmaceutical product & regardless of causal relationship with this treatment. It can be any unfavorable & unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether/not considered related to it. AEs were graded per NCI CTCAE v4.0.Grade 1=Mild; asymptomatic/mild symptoms; clinical /diagnostic observations only; intervention not indicated; Grade 2=Moderate; minimal, local/non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL);Grade 3= Severe/medically significant, but not immediately life-threatening; hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4=Life-threatening consequences/urgent intervention indicated; Grade 5=Death related to AE. OLE population=all participants who received at least 1 dose of open label etrolizumab in Part 1.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
        AEs, Any Grade
    1431
        Grade 1 AEs
    315
        Grade 2 AEs
    679
        Grade 3 AEs
    405
        Grade 4 AEs
    23
        Grade 5 AEs
    9
    No statistical analyses for this end point

    Primary: Part 1: Percentage of Participants With Endoscopic Remission

    Close Top of page
    End point title
    Part 1: Percentage of Participants With Endoscopic Remission [5]
    End point description
    The Mayo scoring system is a composite of 4 assessments for UC disease activity. The 4 component sub-scores are: 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment, each rated from 0‑3, 0 representing no pathology to 3 for severe disease. The minimum Mayo Score is 0 (no pathology) and the maximum is 12 (severe disease). Endoscopic remission was defined as Mayo Endoscopic subscore = 0. Percentage has been rounded off. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study. Number analyzed is the number of participants with data available for analysis.
    End point type
    Primary
    End point timeframe
    At OLE Week 108
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    900
    Units: percentage of participants
        number (not applicable)
    45.7
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With Infection Related AEs and Severity of Infection-Related AEs Assessed Using NCI CTCAE v4.0

    Close Top of page
    End point title
    Part 1: Number of Participants With Infection Related AEs and Severity of Infection-Related AEs Assessed Using NCI CTCAE v4.0 [6]
    End point description
    AE=untoward medical occurrence in participant administered a pharmaceutical product & regardless of causal relationship with this treatment. It can be any unfavorable & unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether/not considered related to it. AEs were graded per NCI CTCAE v4.0.Grade 1=Mild; asymptomatic/mild symptoms; clinical/diagnostic observations only; intervention not indicated; Grade 2=Moderate; minimal, local/non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3= Severe/medically significant, but not immediately life-threatening; hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4=Life-threatening consequences/urgent intervention indicated; Grade 5=Death related to AE. OLE population=all participants who received at least 1 dose of open label etrolizumab in Part 1.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
        Infection Related AEs, Any Grade
    825
        Infection Related AEs, Grade 1
    576
        Infection Related AEs, Grade 2
    423
        Infection Related AEs, Grade 3
    96
        Infection Related AEs, Grade 4
    6
        Infection Related AEs, Grade 5
    1
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With Serious Infection Related AES

    Close Top of page
    End point title
    Part 1: Number of Participants With Serious Infection Related AES [7]
    End point description
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
    110
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With Injection Site Reactions and Severity of Injection Site Reactions Assessed Using NCI CTCAE v4.0

    Close Top of page
    End point title
    Part 1: Number of Participants With Injection Site Reactions and Severity of Injection Site Reactions Assessed Using NCI CTCAE v4.0 [8]
    End point description
    AE=untoward medical occurrence in participant administered a pharmaceutical product & regardless of causal relationship with this treatment. It can be any unfavorable & unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether/not considered related to it. Injection-site reaction=any local reaction occurring at site of injection following drug administration. Signs (e.g. erythema, induration/swelling) & symptoms (e.g. pain, pruritus). Injection site reactions were graded as per NCI CTCAE v4.0. Grade 1=Tenderness with/without associated symptoms (e.g., warmth, erythema, itching); Grade 2=Pain; lipodystrophy; edema; phlebitis; Grade 3=Ulceration/necrosis; severe tissue damage; operative intervention indicated; Grade 4=life-threatening consequences/urgent intervention indicated; Grade=5 death related to AE. OLE population= all participants who received at least one dose of open label etrolizumab in Part 1.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
        Injection Site Reactions, Any Grade
    32
        Injection Site Reactions, Grade 1
    28
        Injection Site Reactions, Grade 2
    5
        Injection Site Reactions, Grade 3
    0
        Injection Site Reactions, Grade 4
    0
        Injection Site Reactions, Grade 5
    0
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants With AEs Leading to Etrolizumab Discontinuation

    Close Top of page
    End point title
    Part 1: Number of Participants With AEs Leading to Etrolizumab Discontinuation [9]
    End point description
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a Etrolizumab, whether or not considered related to the medicinal (investigational) product. Number of participants who discontinued etrolizumab treatment during the OLE period have been reported here. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1773
    Units: participants
    234
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants with Malignancies

    Close Top of page
    End point title
    Part 1: Number of Participants with Malignancies [10]
    End point description
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Number of participants who developed malignancies during the OLE period have been reported here. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1173
    Units: participants
    38
    No statistical analyses for this end point

    Primary: Part 1: Number of Participants with Hypersensitivity Reactions and Severity of Hypersensitivity Assessed Using NCI-CTCAE v4.0

    Close Top of page
    End point title
    Part 1: Number of Participants with Hypersensitivity Reactions and Severity of Hypersensitivity Assessed Using NCI-CTCAE v4.0 [11]
    End point description
    AE is any untoward medical occurrence in participant administered a pharmaceutical product & regardless of causal relationship with this treatment. It can be any unfavorable & unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether/not considered related to it. Hypersensitivity was assessed as per NCI CTCAE v4.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3=Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. OLE Population included all participants who received at least one dose of open label etrolizumab in Part 1 of the study.
    End point type
    Primary
    End point timeframe
    From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years)
    Notes
    [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 1 (OLE): Etrolizumab
    Number of subjects analysed
    1173
    Units: participants
        Hypersensitivity Reactions, Any Grade
    85
        Hypersensitivity Reactions, Grade 1
    65
        Hypersensitivity Reactions, Grade 2
    19
        Hypersensitivity Reactions, Grade 3
    4
    No statistical analyses for this end point

    Primary: Part 2: Number of Participants with Confirmed Progressive Multifocal Leukoencephalopathy (PML) During the Post-Treatment PML Monitoring Period

    Close Top of page
    End point title
    Part 2: Number of Participants with Confirmed Progressive Multifocal Leukoencephalopathy (PML) During the Post-Treatment PML Monitoring Period [12]
    End point description
    PML Safety Monitoring population included all participants who entered the PML SM period. No treatment was administered in PML SM period, and hence participants entering from Part 1 (OLE) and the parent studies have been reported together.
    End point type
    Primary
    End point timeframe
    From end of safety follow-up in Part 1 or Phase II/III parent studies up to a maximum of 92 weeks
    Notes
    [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical analysis was planned for this endpoint.
    End point values
    Part 2: PML-SM
    Number of subjects analysed
    796
    Units: participants
    0
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Part 1 (OLE): From Day 1 up to end of 12-week safety follow up in OLE (approximately 7 years); Part 2 (PML SM): From end of safety follow-up in Part 1 or Phase II/III parent studies up to a maximum of 92 weeks
    Adverse event reporting additional description
    OLE population included all participants who received at least one dose of open label etrolizumab in Part 1 (OLE) of the study. PML SM population included all participants who entered the PML SM period. Part 2: PML SM arm includes all participants who entered PML SM from Part 1 (OLE) & from their respective parent studies.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Part 2 (PML SM)
    Reporting group description
    Participants from Part 1 (OLE) and from Phase II/III studies who were not eligible/did not wish to enroll in Part 1 (OLE) and had completed the 12-week safety follow-up period were enrolled in the Part 2 (PML SM). Participants were monitored for PML for a maximum of 92-weeks, during which no etrolizumab treatment was administered.

    Reporting group title
    Part 1 (OLE): Etrolizumab
    Reporting group description
    Participants received etrolizumab 105 mg, SC, Q4W for maximum of 369.9 weeks, followed by a 12-week safety follow-up.

    Serious adverse events
    Part 2 (PML SM) Part 1 (OLE): Etrolizumab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 796 (0.25%)
    373 / 1773 (21.04%)
         number of deaths (all causes)
    1
    9
         number of deaths resulting from adverse events
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Papillary thyroid cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Adenoma benign
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metastatic renal cell carcinoma
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intraductal papillary breast neoplasm
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hodgkin's disease
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tumour perforation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal adenocarcinoma
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatic carcinoma metastatic
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Breast cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung adenocarcinoma
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myeloid leukaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Ovarian cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Adenocarcinoma of colon
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colorectal adenoma
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colon cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ovarian stromal cancer
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Squamous cell carcinoma of pharynx
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal neoplasm
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine leiomyoma
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Deep vein thrombosis
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombosis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Phlebitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Orthostatic hypotension
         subjects affected / exposed
    1 / 796 (0.13%)
    0 / 1773 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pre-eclampsia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abortion
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Sudden death
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Chest pain
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Inflammation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug withdrawal syndrome
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sudden cardiac death
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Hyperthermia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Paraphimosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ovarian cyst
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abnormal uterine bleeding
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cervical dysplasia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acquired hydrocele
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cervical polyp
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endometriosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pelvic pain
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Hydrothorax
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchial obstruction
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleurisy
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthmatic crisis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Post-traumatic stress disorder
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Product issues
    Device dislocation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Cytomegalovirus test positive
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza A virus test positive
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Injury
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epiphyseal fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hand fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Contusion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine perforation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Periprocedural myocardial infarction
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Radius fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thoracic vertebral fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fracture displacement
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary contusion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shoulder fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Joint injury
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscle strain
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthropod bite
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Clavicle fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Foot fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sternal fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Concussion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Craniofacial fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ligament sprain
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spondylolysis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Exposure to communicable disease
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Joint dislocation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Femur fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Procedural pain
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epidural haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Heart disease congenital
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tethered oral tissue
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac failure congestive
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Angina pectoris
         subjects affected / exposed
    0 / 796 (0.00%)
    4 / 1773 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angina unstable
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary artery occlusion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Paroxysmal atrioventricular block
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute coronary syndrome
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary artery stenosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Palpitations
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 796 (0.13%)
    0 / 1773 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sciatica
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Multiple sclerosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Pancytopenia
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lymphadenopathy
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemolytic anaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia vitamin B12 deficiency
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukaemoid reaction
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    16 / 1773 (0.90%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 19
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Retinal detachment
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspepsia
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal polyp
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal dysplasia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Strangulated umbilical hernia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malocclusion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemorrhoids thrombosed
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Proctitis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colon dysplasia
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal polyp
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis chronic
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colonic fistula
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain lower
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    0 / 796 (0.00%)
    5 / 1773 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Autoimmune pancreatitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anal fistula
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal haemorrhage
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Irritable bowel syndrome
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 796 (0.00%)
    6 / 1773 (0.34%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    1 / 796 (0.13%)
    131 / 1773 (7.39%)
         occurrences causally related to treatment / all
    0 / 1
    4 / 153
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 796 (0.00%)
    4 / 1773 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestine polyp
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Food poisoning
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic cirrhosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Biliary colic
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Granuloma skin
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angioedema
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erythema
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erythema nodosum
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Glomerulonephritis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pelvi-ureteric obstruction
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal colic
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder perforation
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    0 / 796 (0.00%)
    10 / 1773 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 14
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ureterolithiasis
         subjects affected / exposed
    0 / 796 (0.00%)
    5 / 1773 (0.28%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Rotator cuff syndrome
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthritis reactive
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthropathy
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthritis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Seronegative arthritis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tendon laxity
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ankylosing spondylitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal stenosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Flank pain
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Cystitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronavirus infection
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal infection
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    1 / 796 (0.13%)
    13 / 1773 (0.73%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 13
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacterial salpingitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Meningitis listeria
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    0 / 796 (0.00%)
    4 / 1773 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Endometritis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peritonitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Appendiceal abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 796 (0.00%)
    11 / 1773 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis norovirus
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Folliculitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cytomegalovirus colitis
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tuberculous pleurisy
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestine infection
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peritonsillar abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Campylobacter gastroenteritis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 796 (0.00%)
    10 / 1773 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cytomegalovirus infection
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 796 (0.00%)
    6 / 1773 (0.34%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Focal peritonitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Disseminated tuberculosis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis salmonella
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sinusitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Salmonellosis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bone abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal viral infection
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal sepsis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epstein-Barr virus infection
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Complicated appendicitis
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory syncytial virus infection
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Latent tuberculosis
         subjects affected / exposed
    0 / 796 (0.00%)
    3 / 1773 (0.17%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacterial infection
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 796 (0.00%)
    2 / 1773 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anal abscess
         subjects affected / exposed
    0 / 796 (0.00%)
    7 / 1773 (0.39%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Obesity
         subjects affected / exposed
    0 / 796 (0.00%)
    1 / 1773 (0.06%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Part 2 (PML SM) Part 1 (OLE): Etrolizumab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 796 (0.25%)
    1052 / 1773 (59.33%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 796 (0.00%)
    134 / 1773 (7.56%)
         occurrences all number
    0
    187
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 796 (0.00%)
    128 / 1773 (7.22%)
         occurrences all number
    0
    149
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 796 (0.00%)
    98 / 1773 (5.53%)
         occurrences all number
    0
    117
    Colitis ulcerative
         subjects affected / exposed
    2 / 796 (0.25%)
    587 / 1773 (33.11%)
         occurrences all number
    2
    882
    Diarrhoea
         subjects affected / exposed
    0 / 796 (0.00%)
    95 / 1773 (5.36%)
         occurrences all number
    0
    114
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 796 (0.00%)
    128 / 1773 (7.22%)
         occurrences all number
    0
    172
    Infections and infestations
    COVID-19
         subjects affected / exposed
    0 / 796 (0.00%)
    165 / 1773 (9.31%)
         occurrences all number
    0
    178
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 796 (0.00%)
    110 / 1773 (6.20%)
         occurrences all number
    0
    157
    Influenza
         subjects affected / exposed
    0 / 796 (0.00%)
    100 / 1773 (5.64%)
         occurrences all number
    0
    121
    Nasopharyngitis
         subjects affected / exposed
    0 / 796 (0.00%)
    226 / 1773 (12.75%)
         occurrences all number
    0
    344

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    24 Jan 2014
    1. The dose for each etrolizumab subcutaneous administration is changed from 100 mg to 105 mg. 2. Exclusion criterion has been amended to reflect that participants who developed cytomegalovirus (CMV) colitis were allowed to continue in the Phase III controlled studies following appropriate and successful treatment completion. 3. Exclusion criterion for participants that received fecal transplant during Phase III controlled studies has been removed. 4. Table 1 has been amended to reflect that in GA28950 controlled Phase III study any U.S. participants receiving immunosuppressants are to stop immunosuppressant use at Week 10. U.S. participants continuing on immunosuppressants after Week 10 are not permitted to enroll in the Part 1 (OLE) of this (GA28951) study. 5. In Table 1, footnote definitions of Clinical Relapse and Disease Worsening have been corrected. 6. It has been clarified that participants who were determined to be hepatitis B core antibody positive in the Phase III study should have hepatitis B DNA measured at defined timepoints in this (GA28951) study.
    30 Mar 2014
    1. The PML Assessment and Monitoring sections have been modified to include the PML Subjective Checklist (symptom assessment) and the PML Objective Checklist (neurologic evaluation) that are to be conducted according to the Schedule of Assessments. 2. Algorithm for the Evaluation of PML has been updated. 3. The UC disease activity sections have been updated to record stool frequency and rectal bleeding score for 5 days prior to clinic visit instead of recording daily. 4. Pharmacokinetic sample collection is added to schedule of assessment section.
    04 Jul 2014
    1. Risk mitigation strategy, including the potential risks associated with etrolizumab treatment and the risks associated with disease worsening has been updated in relevant sections. 2. The inclusion criterion regarding contraception use for women has been updated and a new appendix (Appendix 4) has been included. 3. Definition and reporting process of a Suspected Unexpected Serious Adverse Reaction (SUSAR) have been updated. 4. Footnote g in Appendix 1 (Schedule of Assessments) has been updated to clarify that results of the JCV antibody tests should be provided and discussed with the participants annually.
    01 Aug 2014
    1. The eligibility criteria for enrollment into Part 1 of OLE-SM GA28951 were amended to align with the design change in the Hibiscus studies. The achievement or non-achievement of clinical response criterion to enter OLE at Week 10 was updated to clinical remission. The language on the rescue medication was also updated according to the Hibiscus changes. 2. A new footnote for was added to include the definition of clinical remission. 3. Inclusion Criteria updated reducing the waiting time from 4 to 2 weeks for eligible participants to be transferred from Hibiscus to Part 1 of OLE-SM Study GA28951 after the Week 10 timepoint. 4. Inclusion Criteria updated to clarify when the first open-label etrolizumab dose can be administered to the participants who completed the Hibiscus studies at Week14. 5. Sections were updated to indicate new post-study adverse event reporting information. 7. “Unscheduled Visit” column, a “PML Objective Checklist” row, and extra footnotes added to Appendix 3 to clarify the assessments performed at the clinic in the event that the participants reports signs or symptoms of PML in between the scheduled site calls every 6 months.
    13 Jan 2015
    1. The eligibility criteria for enrollment amended to reflect that participants are to receive their first dose of etrolizumab in Study GA28951 4 weeks after their last dose of study medication in controlled Phase III Hibiscus studies, GA28948 and GA28949. 2. A new footnote added to include the definition of clinical remission. 3. Safety sub-sections updated. 5. A new section regarding protocol deviations was added. 6. A new “Unscheduled Visit” column, a “PML Objective Checklist” row was added to clarify the assessments performed at the clinic in the event that the participants reports signs or symptoms of PML in between the scheduled site calls every 6 months.
    05 Sep 2017
    1. Details about the number of participants exposed to etrolizumab was removed 2. Details on contraception methods was removed from the inclusion criteria. 3. Anti-therapeutic antibody samples must be collected at Week 0 if the Week 0 visit occurs > 7 days after the final visit of the Phase II OLE or Phase III controlled study.
    12 Feb 2019
    1. Language in the Background section was amended to align with the other ulcerative colitis studies in the Etrolizumab Phase III Program. 2. The duration of Part 1 OLE was updated to approximately 9 years. 3. Number of participants potentially enrolling in this study was updated to approximately 2100. 4. Janus kinase inhibitors added to the list of rescue therapies prohibited at any time during the study. 5. References to "Latvia/Lithuania" changed to "VHP" to reflect inclusion of all countries participating in the Voluntary Harmonisation Procedure. 6. Clarification regarding the reporting of adverse events related to medical device complaints in individuals other than the study participants added. 7. Procedures for adverse event reporting updated to clarify that sites are not expected to review participant-reported outcome data for adverse events.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    05 Oct 2023
    The study was terminated due to the Sponsor’s decision to not pursue a marketing application for etrolizumab in adult UC indication.
    -

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 16:07:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA